A number of drugs were examined for their ability to change the concentration of 5-hydroxytryptamine in mouse brain and in whole mice treated with 5-hydroxytryptophan. After f-phenylisopropylhydrazine or iproniazid, two inhibitors of monoamine oxidase, the brain 5-hydroxytryptamine rose to a maximum value in 8 hr., after which it declined, although a slight rise remained for as long as 6 days. Dose-effect relationships, determined 6 hr. after administration, showed fl-phenylisopropylhydrazine to be approximately 60 times as effective as iproniazid in raising the brain 5-hydroxytryptamine. When mice were given 5-hydroxytryptophan and the amine content of the whole mice estimated, pretreatment with /-phenyiisopropylhydrazine increased their 5-hydroxytryptamine content whereas pretreatment with iproniazid did not change it. The concentration of the amine in mouse brain and in whole mice was lower after reserpine, but was raised when reserpine and fl-phenylisopropylhydrazine were given together. A small rise in brain 5-hydroxytryptamine was found after chlorpromazine; when chlorpromazine was given with iproniazid, however, the resulting increase was less than that found after iproniazid alone. Brain 5-hydroxytryptamine was unaltered after prolonged treatment with morphine.
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Monoamine oxidase is widely distributed in animal tissues and is an important route for the inactivation of 5-hydroxytryptamine (Davison, 1958; Keglevic, Supek, Kveder, Iskric', Keckes, and Kisic, 1959) . Effective inhibitors of monoamine oxidase should therefore retard the inactivation of the amine in vivo, but this is only partially true for l-isonicotinyl-2-isopropylhydrazine (iproniazid), the most widely used inhibitor of monoamine oxidase. Although iproniazid is a strong and fairly specific inhibitor of this enzyme in homogenates (Zeller, Barsky, Fouts, Kircheimer, and Van Orden, 1952; Zeller, Barsky, and Berman, 1955) , it has little effect on the inactivation of 5-hydroxytryptamine in tissue slices or in intact mice (Udenfriend, Weissbach, and Bogdanski, 1957) . More recently, Horita (1958) has reported f3-phenylisopropylhydrazine to be a potent inhibitor of monoamine oxidase.
In the present experiments, both /3-phenylisopropylhydrazine and iproniazid were examined as inhibitors of 5-hydroxytryptamine inactivation in intact mice. 5-Hydroxytryptamine is present in the nervous system of a wide variety of species (Amin, Crawford, and Gaddum, 1954; Correale, 1956) , and this has led to much interest in possible relationships between 5-hydroxytryptamine and drugs which affect brain function (Gaddum, 1954; Woolley and Shaw, 1954; Brodie, Pletscher, and Shore, 1955; Paasonen and Vogt, 1956 ; Pletscher, 1957 Vane (1957) . The fundus strip was suspended in a 10 ml. bath of oxygenated Tyrode solution at 370, and contractions were recorded from a pendular lever (Paton, 1957) . Atropine sulphate was added to the Tyrode solution to give a concentration of 10'.
Paper Chromatography.-Acetone extracts were evaporated to dryness at 350, and the residue extracted with 0.25 ml. N HCI and 3 ml. ether. After shaking, the ether layer was discarded, and the aqueous phase transferred to an evaporating dish with 2 ml. alcohol. The extract was concentrated to 0.1 to 0.2 ml. and applied to a sheet of Whatman No. 1 paper together with marker spots of tryptamine, 5-hydroxytryptamine and tryptophan. Chromatograms were developed by the descending technique with isopropanol/ammonia (880)/water (20:1:2), or with n-butanol/acetic acid glacial/water (12:3:5).
Occasionally two-way chromatograms were prepared with the same two solvent systems. All chromatograms were run for 5.5 to 7 hr. at a room temperature of 25.5 to 29.5°. Indoles were detected on the dried chromatograms by spraying with a 2% solution of p-dimethylaminobenzaldehyde in N HCl (Ehrlich's reagent), followed by heating at 80 to 85°for 3 to 5 min.
RESULTS

Identification of 5-Hydroxytryptamine in
Extracts.-When bromolysergic acid diethylamide at a concentration of 10-7 was included in the de Jalon solution, the uterine responses to both 5-hydroxytryptamine and extracts were almost always abolished. Occasionally a brain extract still had a very slight stimulant action indicating the presence of a trace of interfering substance, but it was clear that the extracts reacted mainly with tryptamine receptors (Gaddum, 1953 Gaddum and Hameed, 1954) .
Tryptamine has been identified in guinea-pig brain after administration of tryptophan and iproniazid (Hess, Redfield, and Udenfriend, 1959) . Tryptamine and 5-hydroxytryptamine both react with tryptamine receptors and both are substrates of monoamine oxidase. The extracts were therefore examined for tryptamine, since this might have accounted for a significant part of their stimulant activity on the uterus. In extracts of mouse brains and whole mice 5-hydroxytryptamine was identified chromatographically as a blue spot with an RF of 0.49 in butanol/acetic, and an RF of 0.48 in isopropanol / ammonia. Tryptamine was not detected on these chromatograms. Even so, it seemed possible that tryptamine was present in small amounts. Tryptamine and 5-hydroxytryptamine can now be differentiated biologically, since Vane (1959) has shown that inhibitors of monoamine oxidase potentiate the response of the rat fundus preparation to tryptamine but not to 5-hydroxytryptamine. Tryptamine, 5-hydroxvtryptamine, and brain extracts of normal mice and of mice treated with /?-phenylisopropylhydrazine were tested on rat fundus preparations both before and after the addition of iproniazid 10-5. After HT, 5-hydroxytryptamin (tg.). X, brain extract from control mice (ml.) From IIH, iproniazid 10-5 was present in the Tyrod solution.
Iproniazid potentiated the response ti tryptamine, but did not potentiate the responses t 5-hydroxytryptamine or extract. iproniazid, the response of a fundus to tryptamine was potentiated whereas the contractions produced by 5-hydroxytryptamine and the extracts remained relatively unaffected (Fig. 1) . This was consistent with the view that the active material in the extracts was 5-hydroxytryptamine rather than tryptamine.
The Effect of Drugs on Uterine Response to 5-Hydroxytryptamine.-The following drugs were added to the organ bath at the same time as 5-hydroxytryptamine: 0.5 ,ug. reserpine, 2 Mtg. chlorpromazine, 30 ,ug. iproniazid, 10 jpg. /3-phenylisopropylhydrazine, and 100 pg. morphine. The response to 5-hydroxytryptamine was reduced after chlorpromazine but was unaffected by the other drugs. When brain extracts of mice treated with chlorpromazine were tested there was no inhibition of the response to 5-hydroxytryptamine, however, showing that the extracts contained insufficient chlorpromazine to affect the uterus.
Recovery of 5-Hydroxytryptamine.-The extraction procedures adopted were similar to those of Correale (1956) . The recovery of 5-hydroxytryptamine was tested by the addition of 0. (100 mg./kg.) and iproniazid (300 mg./kg.) were also investigated at more closely spaced time intervals over a period of 24 hr. (Fig. 2) . The maximum increases in amine were found 8 hr. after administration of either compound. However, for practical reasons the effect of different doses of f3-phenylisopropylhydrazine and iproniazid in raising the brain 5-hydroxytryptamine was investigated after 6 hr. (Fig. 3) . The dose-effect curve for iproniazid had a flatter slope and a lower maximum than the corresponding curve for /3-phenylisopropylhydrazine. It was not possible therefore to give an accurate ratio of the potencies for these two compounds.
However, the effects of 5 mg./kg. /3-phenylisopropylhydrazine and 300 mg. /kg. iproniazid were of the same order, since they increased the brain 5-hydroxytryptamine by 0.347 Mig. /g. and by 0.389 Ilxg./g., respectively. Table II shows differences in the 5-hydroxytryptamine concentration of mouse brain 6 hr. after the intraperitoneal injection of various drugs. The concentration of amine was lower after reserpine (2 mg./kg.), was higher after /3-phenylisopropylhydrazine (20 mg. /kg.), and was increased by the combination of these two drugs at the same dose levels. When all the data were combined as in Table II , the rise in 5-hydroxytryptamine after B3-phenylisopropylhydrazine was higher than that after reserpine plus /3-phenylisopropylhydrazine. However, when the comparison was restricted to results determined in parallel, the difference fabetween the two groups was not signibetefiant(P>0.2). A small but significant Ordinate, increase in brain 5-hydroxytryptamine (pg./g.).
Abscissa, interval between injection of compound and extraction of 5-hydroxytryptamine (hr.). Each point is a mean value± S.E.
5-Hydroxytryptamine in Whole Mice
Injected with 5-Hydroxytryptophan.- Table III shows the effect of some drugs on the 5-hydroxytryptamine extracted from mice injected with 5-hydroxytryptophan. All mice received 5-hydroxytryptophan (150 mg./kg.), and 3 hr. later were killed and extracted for 5-hydroxytryptamine. Drugs tested in the mice were administered intraperitoneally at specified periods before injecting the mice with 5-hydroxytryptophan. Treatment with reserpine (2 mg./kg.) lowered the 5-hydroxytryptamine concentration in mice; in animals treated with B-phenylisopropylhydrazine (100 ml./kg.), it was increased above control levels, but values after treatment with iproniazid (300 mg. /kg.) were not significantly different from the controls. 5-Hydroxytryptamine was also increased when P-phenylisopropylhydrazine and reserpine were injected together; indeed, in mice injected with f-phenylisopropylhydrazine plus reserpine it was not significantly different from /3-phenylisopropylhydrazine treated mice (P>0.2). jug. /g. brain accumulating after fl-phenylisopropylhydrazine. The accumulation of 5-hydroxytryptamine in brain after the monoamine oxida-e inhibitors showed that it was synthesized at a high rate; it was calculated that the normal brain content accumulated in about 2.5 hr. after /3-phenylisopropylhydrazine. The (Udenfriend, Witkop, Redfield, and Weissbach, 1958) . The present results therefore support the view that the rise in 5-hydroxytryptamine in brain after B3-phenylisopropylhydrazine and iproniazid was due to inhibition of brain monoamine oxidase. Log dose-effect curves were obtained by plotting increases in brain 5-hydroxytryptamine against doses of /3-phenylisopropylhydrazine or iproniazid.
Sigmoid curves were obtained for both compounds, but the curve for iproniazid had a flatter slope and a lower maximum than the curve for B8-phenylisopropylhydrazine. The lower maximum of its curve suggested that iproniazid might inhibit both formation and inactivation of 5-hydroxytryptamine in the brain. According to Davison (1956) , a metabolite of iproniazid inhibits enzymes requiring pyridoxal phosphate. This supports the present interpretation of the log dose-effect curve for iproniazid, since pyridoxal phosphate is a co-enzyme of the decarboxylase which forms brain 5-hydroxytryptamine.
Inhibition of 5-hydroxytryptamine inactivation by /3-phenylisopropylhydrazine must be widespread in the tissues of the mouse, since the 5-hydroxytryptamine content of animals injected with 5-hydroxytryptophan was increased after treatment with 8-phenylisopropylhydrazine (100 mg. /kg.). This was a severe test of the effect of 3-phenylisopropylhydrazine, since the substrate was presented to the enzyme in vivo; iproniazid tested in the same way was without effect at 300 mg. / kg.
After reserpine (2 mg. /kg.), 5-hydroxytryptamine was reduced by 63 % in mouse brain and by 30%/ in whole mice. When /3-phenylisopropylhydrazine was given with reserpine, the 5-hydroxytryptamine concentrations of mouse brain and whole mice were raised, suggesting that monoamine oxidase is involved in the disappearance of 5-hydroxytryptamine after reserpine. The 5-hydroxytryptamine content of mice injected with 5-hydroxytryptophan and 83-phenylisopropylhydrazine remained unaltered when the mice were pretreated with reserpine. This showed that reserpine (2 mg. / kg.) had no appreciable effect on the decarboxylation of 5-hydroxytryptophan, which is in agreement with Brodie, Tomich, Kuntzman and Shore (1957) . The difference between the increase in brain 5-hydroxytryptamine found after reserpine plus /3-phenylisopropylhydrazine and that found after P-phenylisopropylhydrazine alone was not significant when the comparison was made between results determined in parallel.
The increase in brain 5-hydroxytryptamine concentration found after iproniazid plus chlorpromazine was significantly less than the increase found after iproniazid alone. This suggested a depression of 5-hydroxytryptamine formation after chlorpromazine. According to West (1958) , chlorpromazine inhibits the 5-hydroxytryptophan decarboxylase of rat kidney in vivo. Such a decarboxylase inhibitor would be expected to cause a fall in brain 5-hydroxytryptamine within Weissbach (1958) , 5-hydroxytryptamine can be inactivated by cytochrome oxidase, an enzyme which is known to be inhibited by chlorpromazine in vitro (Bernsohn, Namajuska and Boshes, 1956; Dawkins, Judah, and Rees, 1959) . Costa and Himwich (1958) found a lowered 5-hydroxytryptophan decarboxylase activity in rabbit brain after convulsive doses of insulin, although the concentration of brain 5-hydroxytryptamine was raised or unaltered. Their results suggest that insulin, like chlorpromazine, depresses turnover of cerebral 5-hydroxytryptamine.
